Trial
NCT04985136
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
—
Condition
Advanced Hepatocellular Carcinoma (HCC)
Intervention
camrelizumab；Rivoceranib
Why stopped
Sponsor R \& D Strategy Adjustment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-01